032300 — Korea Pharma Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩186bn
- KR₩168bn
- KR₩83bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 66,136 | 71,510 | 79,577 | 81,029 | 83,240 |
Cost of Revenue | |||||
Gross Profit | 33,123 | 34,157 | 35,903 | 35,427 | 36,922 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 59,791 | 66,906 | 74,563 | 74,842 | 79,302 |
Operating Profit | 6,346 | 4,604 | 5,014 | 6,187 | 3,939 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,958 | 3,768 | 5,208 | -1,780 | 2,014 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,528 | 3,159 | 6,368 | -1,119 | 83.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 5,528 | 3,159 | 6,368 | -1,119 | 83.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,528 | 3,159 | 6,368 | -1,119 | 83.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 682 | 396 | 584 | -108 | 147 |
Dividends per Share |